中西医结合治疗盆腔炎性疾病临床疗效观察及安全性评价

Integrative Medicine Pelvic Inflammatory Disease Clinical Efficacy and Safety Evaluation

目的:探讨盆腔炎性疾病患者采用中西医结合治疗临床疗效及其安全性,为临床诊断治疗提供一定的参考价值。方法:120例患者根据随机数字表法随机分为对照组(n=60)和观察组(n=60)。对照组采用西药治疗,观察组在对照组基础上结合中药内服和中药保留灌汤治疗。两组均以10天为1个疗程。结果:观察组治疗后总有效率(96.67%)显著高于对照组(81.67%),且有统计学差异(P<0.05);观察组治疗后CD4+、CD4+/CD8+显著高于对照组,而CD8+显著低于对照组,且有统计学差异(P<0.05);观察组治疗后CRP、WBC均显著低于对照组,且有统计学差异(P<0.05);两组患者复发率比较差异不具有统计学差异(P>0.05);两组患者治疗过程中均未发生明显不良反应。结论:盆腔炎性疾病患者采用中西医结合治疗临床疗效显著,具有重要临床研究价值,值得研究推广。

Objective： To investigate the use of pelvic inflammatory disease in patients in combination therapy clinical efficacy and safety,to provide a reference value for clinical diagnosis and treatment. Methods： The group of 120 patients were randomly divided into control group（ n = 60） and observation group（ n = 60） according to a random number table.The control group with western medicine,internal medicine,and the observation group combines traditional Chinese medicine treatment in the control group retained clyster basis. The two groups are 10 d for a course of treatment. Results： The total treatment efficiency（ 96. 67%） was significantly higher（ 81. 67%）,and there is statistically significant（ P〈0. 05）; observation group after treatment CD4^＋,CD4^＋/ CD8^＋was significantly higher,while CD8^＋was significantly lower than the control group,and there are significant differences（ P〈0. 05）; observation group after treatment CRP,WBC were significantly lower than the control group,and there are significant differences（ P〈0. 05）; difference between the two groups of patients relapse rate does not have a statistically significant difference（ P〈0. 05）; treatment groups did not occur in patients with significant adverse reactions. Conclusion： Patients pelvic inflammatory disease using combination therapy significant clinical effect has important clinical research value,worthy of study promotion.